Healthcare / BiotechnologyTaiwan
$41.85
+0.45 (+1.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.5B · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.3%
↓Gross Margin
-109.9%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+161.6%
FCF CAGR
—
FCF margin
-417.9%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $401.0M · net income $-1.50B · FCF $-1.68B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $401.0M | $401.0M | $34.7M | $61.4M | $22.4M |
| Net Income | $-1.50B | $-1.50B | $-1.38B | $-2.14B | $-1.64B |
| EBITDA | $-1.09B | $-1.09B | $-1.04B | $-1.75B | $-1.30B |
| EPS | — | — | -8.90 | -16.44 | -13.70 |
| Gross Margin | -109.9% | -109.9% | 23.9% | 97.2% | -86.4% |
| Operating Margin | -344.6% | -344.6% | -3912.4% | -3420.8% | -7166.2% |
| Net Margin | -374.1% | -374.1% | -3983.9% | -3480.0% | -7325.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 1.85 | 2.11 | 1.32 |
| Current Ratio | 1.33 | 1.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.68B | $-1.68B | $-1.26B | $-1.51B | $-1.43B |
| Returns | |||||
| ROE | -26.3% | -26.3% | -154.7% | -260.3% | -117.9% |
| Valuation | |||||
| P/B | 1.95 | 1.95 | 10.93 | 10.00 | 8.97 |
| Growth & Yield | |||||
| Revenue Growth | 1056.3% | 1056.3% | -43.5% | 174.1% | — |
| EPS Growth | — | — | 45.9% | -20.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.90 → n/d
Residual
-23.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.